Highlights of This Issue 1

SMALL MOLECULE THERAPEUTICS

3 Repurposing the Antihelmintic Mebendazole as a Hedgehog Inhibitor
Andrew R. Larsen, Ren-Yuan Bai, Jon H. Chung, Alexandra Borodovsky, Charles M. Rudin, Gregory J. Riggins, and Fred Bunz

14 TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90α and β, Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models
Shuichi Ohkubo, Yasuo Kodama, Hiromi Muraoka, Hiroko Hitotsumachi, Chihoko Yoshimura, Makoto Kitade, Akihito Hashimoto, Kenjiro Ito, Akira Gomori, Koichi Takahashi, Yoshihiro Shibata, Akira Kanoh, and Kazuhiko Yonekura

23 Darinaparsin Inhibits Prostate Tumor–Initiating Cells and Du145 Xenografts and Is an Inhibitor of Hedgehog Signaling
Nitu Bansal, Nadine Johnson Farley, Lisa Wu, Jonathan Lewis, Hagop Youssoufian, and Joseph R. Bertino

31 Preclinical Characterization of RSM-932A, a Novel Anticancer Drug Targeting the Human Choline Kinase Alpha, an Enzyme Involved in Increased Lipid Metabolism of Cancer Cells
Juan Carlos Lacal and Joaquín M. Campos

40 Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer
Melissa R. Junttila, Vidusha Devasthali, Jason H. Cheng, Joseph Castillo, Ciara Metcalfe, Anne C. Clermont, Douglas Den Otter, Emily Chan, Hani Bou-Reslan, Tim Cao, William Forrest, Michelle A. Nannini, Dorothy French, Richard Carano, Mark Merchant, Klaus P. Hoeflich, and Mallika Singh

48 Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
Urs Hancox, Sabina Cosulich, Lyndsey Hanson, Cath Trigwell, Carol Lenaghan, Rebecca Ellston, Hannah Dry, Claire Crafer, Bernard Barlaam, Martina Fitzek, Paul D. Smith, Donald Ogilvie, Celina D’Cruz, Lillian Castriotta, Stephen R. Wedge, Lara Ward, Steve Powell, Mandy Lawson, Barry R. Davies, Elizabeth A. Harrington, Emily Foster, Marie Cumberbatch, Stephen Green, and Simon T. Barry

59 Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
Paul J. Toren, Soojin Kim, Steven Pham, Azza Mangalji, Hans Adomat, Emma S. Tomlinson Guns, Amina Zoubeidi, William Moore, and Martin E. Gleave

70 Radioprotection of the Brain White Matter by Mn(III) N-Butoxyethylpyridylporphyrin–Based Superoxide Dismutase Mimic MnTnBuOE-2-PyP5+.1

80 Small Molecule Inhibitor YM155-Mediated Activation of Death Receptor 5 Is Crucial for Chemotherapy-Induced Apoptosis in Pancreatic Carcinoma
Xiangxuan Zhao, William M. Puszky, Zaiming Lu, David A. Ostrov, Thomas J. George, Keith D. Robertson, and Chen Liu

90 The Protein Phosphatase 2A Inhibitor LB100 Sensitizes Ovarian Carcinoma Cells to Cisplatin-Mediated Cytotoxicity
Ki-Eun Chang, Bih-Rong Wei, James P. Madigan, Matthew D. Hall, R. Mark Simpson, Zhengqing Zhuang, and Michael M. Gottesman

101 Combination Strategy Targeting VEGF and HGF/c-met in Human Renal Cell Carcinoma Models
Eric Ciamporcero, Kiersten Marie Miles, Remi Adelaiye, Swathi Ramakrishnan, Li Shen, ShengYu Ku, Stefania Pizzimenti, Barbara Sennino, Giuseppina Barrera, and Roberto Pili

111 Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
Yulian P. Ramirez, Ann C. Mladek, Roger M. Phillips, Mikko Gynther, Jarkko Rautio, Alonzo H. Ross, Richard T. Wheelhouse, and Jann N. Sakaria
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>120</td>
<td>Tumor-Penetrating iRGD Peptide Inhibits Metastasis</td>
<td>Kazuki N. Sugahara, Gary B. Braun, Tatiana Hurtado de Mendoza, Venkata Ramana Kotamraju, Randall P. French, Andrew M. Lowy, Tambet Teesalu, and Erkki Ruoslahti</td>
</tr>
<tr>
<td>129</td>
<td>ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice</td>
<td>Anthony Regina, Michel Demeule, Sasmita Tripathy, Simon Lord-Dufour, Jean-Christophe Currie, Mustapha Iddir, Borhane Annabi, Jean-Paul Castaigne, and Jean E. Lachowicz</td>
</tr>
<tr>
<td>141</td>
<td>Near Infrared Photoimmunotherapy in the Treatment of Disseminated Peritoneal Ovarian Cancer</td>
<td>Kazuhide Sato, Hirofumi Hanaoka, Rira Watanabe, Takahito Nakajima, Peter L. Choyke, and Hisataka Kobayashi</td>
</tr>
<tr>
<td>151</td>
<td>Bicyclic Peptides Conjugated to an Albumin-Binding Tag Diffuse Efficiently into Solid Tumors</td>
<td>Lisa Pollaro, Sandeep Raghunathan, Julia Morales-Sanfrutos, Alessandro Angelini, Stephan Kontos, and Christian Heinis</td>
</tr>
<tr>
<td>162</td>
<td>Preclinical Pharmacokinetics, Tolerability, and Pharmacodynamics of Metuzumab, a Novel CD147 Human–Mouse Chimeric and Glycoengineered Antibody</td>
<td>Zheng Zhang, Yang Zhang, Qian Sun, Fei Feng, Muren Huhe, Li Mi, and Zhihan Chen</td>
</tr>
<tr>
<td>174</td>
<td>Combined CDKN1A/TP53 Mutation in Bladder Cancer Is a Therapeutic Target</td>
<td>Yang Liu and David J. Kwiatkowski</td>
</tr>
<tr>
<td>183</td>
<td>SRT1720 Induces Lysosomal-Dependent Cell Death of Breast Cancer Cells</td>
<td>Tyler J. Lahusen and Chu-Xia Deng</td>
</tr>
<tr>
<td>193</td>
<td>Mechanisms of Resistance to Cabazitaxel</td>
<td>George E. Duran, Yan C. Wang, E. Brian Francisco, John C. Rose, Francisco J. Martinez, John Collier, Diana Brassard, Patricia Vrignaud, and Branimir I. Sikic</td>
</tr>
<tr>
<td>202</td>
<td>Direct Binding of Arsenic Trioxide to AMPK and Generation of Inhibitory Effects on Acute Myeloid Leukemia Precursors</td>
<td>Elspeth M. Beauchamp, Eva M. Kosciuczuk, Ruth Serrano, Dhaval Nanavati, Elden P. Swindell, Benoit Violett, Thomas V. O’Halloran, Jessica K. Altman, and Leonidas C. Platanias</td>
</tr>
<tr>
<td>213</td>
<td>Midkine Lacking Its Last 40 Amino Acids Acts on Endothelial and Neuroblastoma Tumor Cells and Inhibits Tumor Development</td>
<td>Noushin Dianat, Barbara Le Viet, Emilie Gobbo, Nathalie Auger, Ivan Bëche, Anne-lise Bemaceur-Griscelli, and Frank Griscelli</td>
</tr>
<tr>
<td>225</td>
<td>ANP63α Transcriptionally Activates Chemokine Receptor 4 (CXCR4) Expression to Regulate Breast Cancer Stem Cell Activity and Chemotaxis</td>
<td>Andrew J. DeCastro, Patrimea Cherukuri, Amanda Balboni, and James DiRenzo</td>
</tr>
<tr>
<td>236</td>
<td>Interactions of Multitargeted Kinase Inhibitors and Nucleoside Drugs: Achilles Heel of Combination Therapy?</td>
<td>Vijaya L. Damaraju, Michelle Kuzma, Delores Mowles, Carol E. Cass, and Michael B. Sawyer</td>
</tr>
<tr>
<td>246</td>
<td>Elevated ILM Kinase 1 in Nonmetastatic Prostate Cancer Reflects Its Role in Facilitating Androgen Receptor Nuclear Translocation</td>
<td>Katerina Mardilovich, Mads Gabrielsen, Lynn McGarry, Clare Orange, Rachana Patel, Emma Shanks, Joanne Edwards, and Michael F. Olson</td>
</tr>
<tr>
<td>259</td>
<td>Enhanced Colonic Tumorigenesis in Alkaline Sphingomyelinase (NPP7) Knockout Mice</td>
<td>Ying Chen, Ping Zhang, Shu-Chang Xu, Leping Yang, Ulrikke Voss, Eva Ekblad, Yunjin Wu, Yalan Min, Erik Hertervig, Åke Nilsson, and Rui-Dong Duan</td>
</tr>
<tr>
<td>268</td>
<td>Long Noncoding RNA ANRIL Promotes Non–Small Cell Lung Cancer Cell Proliferation and Inhibits Apoptosis by Silencing KLF2 and P21 Expression</td>
<td>Feng-qi Nie, Ming Sun, Jin-song Yang, Min Xie, Tong-peng Xu, Rui Xia, Yan-wen Liu, Xiang-hua Liu, Er-bao Zhang, Kai-hua Lu, and Yong-qian Shu</td>
</tr>
</tbody>
</table>
Identifying Actionable Targets through Integrative Analyses of GEM Model and Human Prostate Cancer Genomic Profiling

Pharmacological Profiling of Kinase Dependency in Cell Lines across Triple-Negative Breast Cancer Subtypes
Lauren S. Fink, Alexander Beatty, Karthik Devanajan, Suraj Peri, and Jeffrey R. Peterson

The NOTCH Ligand JAGGED2 Promotes Pancreatic Cancer Metastasis Independent of NOTCH Signaling Activation
Yufeng Hu, Hexiu Su, Xu Li, Guoli Guo, Ling Cheng, Renyi Qin, Guoliang Qing, and Hudan Liu

Changes in BAI1 and Nestin Expression Are Prognostic Indicators for Survival and Metastases in Breast Cancer and Provide Opportunities for Dual Targeted Therapies
Walter Hans Meisen, Samuel Dubin, Steven T. Sizemore, Haritha Mathysaraja, Katie Thies, Norman L. Lehman, Peter Boyer, Alena Cristina Jaime-Ramirez, J. Bradley Elder, Kimberly Powell, Arnab Chakravarti, Michael C. Ostrowski, and Balveen Kaur

Tumor antigen–targeting mAbs, such as Herceptin, are critical weapons in the cancer therapeutic arsenal, yet they cross the blood–brain barrier (BBB) poorly and their success treating brain tumors is limited. By conjugating an anti-HER2 mAb with a peptide that utilizes receptor-mediated transcytosis across the BBB, a brain-penetrant mAb, ANG4043, was created. ANG4043’s retention of tumor-targeting properties was demonstrated in HER2-positive BT-474 breast carcinoma cells. Colocalization of the control anti-HER2 mAb and the HER2 antigen is shown in yellow on the cell surface. For details, see article by Regina and colleagues on page 129.
Molecular Cancer Therapeutics

14 (1)


Updated version  Access the most recent version of this article at:  
http://mct.aacrjournals.org/content/14/1

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.